Collectively, we present data demonstrating that combined immunotherapeutic strategy of multi-antigenic cancer vaccines with sustained PD-L1 blockade are able to induce potent tumour-reactive T-cells capable of overcoming the potential immune escaping of clonally heterogeneous myeloid leukaemia, resulting in remarkable therapeutic anti-tumour benefits. The gene discussed is CD274; the disease is cancer.